Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CMChristine MaiARA. RaffyEPEmma Pedrot

Discussion

Loading...

Member takes

Overview

This real-world analysis reveals common combinations and regimens used post-CAR T for relapsed/refractory myeloma, indicating significant lenalidomide refractoriness.

Key Points

  • The median progression-free survival post-CAR T therapy is often less than three years, indicating ongoing challenges in MM care.
  • 52% of patients were lenalidomide-refractory, with treatment often pivoting to elotuzumab and isatuximab-based regimens.
  • Anonymous patient charts were analyzed across EU5 countries, the US, and Japan to uncover treatment regimens after anti-BCMA CAR T therapy.
  • Geographic discrepancies highlight variations in access to distinct therapies, reflecting differing medical policies and practices.

Cite This Study

Mai et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d61ahttps://doi.org/10.1182/blood-2025-7600
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  2. 2Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States2025 · 4 citations
  3. 3Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study2025 · 2 citations
  4. 4Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  5. 5CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025